A new SEC filing for Thermo Fisher Scientific Inc. (TMO) was recorded as of 1 August 2026, prompting renewed examination of the company's financial and ownership profile [Brief - 2026-08-17]. No additional briefing disclosures beyond that filing date were available for the current reporting period. The filing renewed attention to TMO's operational and ownership data ahead of the present report, which was further motivated by recent insider activity and material changes in institutional positioning.
For the trailing twelve months ending 2026-06-27, TMO recorded revenue of $46.34 billion, representing year-over-year growth of approximately 10.5%. Net income over the same period stood at $6.98 billion, yielding a net margin of 15.07%. Gross margin was reported at 24.45% and operating margin at 17.58%. Earnings per share grew 9.35% year-over-year. The company held $4.06 billion in cash against total debt of $45.65 billion. The trailing P/E ratio was 32.45 [SEC 10-Q - TMO - 2026-06-27].
Insider activity over the past 30 days recorded 51 transactions with a net direction of selling, totalling a net disposal value of approximately $22.29 million [SEC Form 4 - TMO - 2026-09]. On the institutional side, five notable managers opened new positions during the most recent reporting period: Citadel (Ken Griffin), D1 Capital (Dan Sundheim), Millennium (Izzy Englander), AQR Capital (Cliff Asness), and Bridgewater (Ray Dalio) each initiated new holdings in TMO [SEC 13F - Citadel - Q2 2026] [SEC 13F - D1Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR - Q2 2026] [SEC 13F - Bridgewater - Q2 2026].
The prevailing macroeconomic backdrop features a 10-year US Treasury yield of 4.83% and a 2-year yield of 4.39%, producing a normal yield curve spread of approximately 44 basis points [FRED DGS10] [FRED DGS2]. This rate environment represents the broader context within which TMO's debt load of $45.65 billion and financing costs are assessed by market participants.